Featured Conference
7th Annual Guidelines for Disseminating Off-Label Information
Balance Scientific Discussion with Promotion in an Environment of Increased Regulatory Scrutiny
October 17-18, 2005 * Arlington, VA
Visit the conference website for more information and to register.
As the drug industry continues to be pursued as an object of investigation and enforcement activity by the FDA, OIG, DOJ, SEC and state agencies, companies are exposed to more risk and more liability for off-label violations. Attend CBI’s annual conference, October 17-18, 2005 in Washington, D.C., and gain insight from the regulatory, marketing, legal and medical communications perspectives. The program provides a unique forum in which you can network with industry executives and medical affairs teams who can share their valuable experiences with you.
The 2005 program covers the latest issues in disseminating off-label information including:
-
The landmark Neurontin case
-
How the Medicare Modernization Act will impact off-label reimbursement
-
Determine strategic planning and budgeting for products that have significant off-label sales
-
How off-label communication should be handled by Medical Science Liaisons
Hear what some of our previous attendees had to say:
“Valuable info provided on medical education – specifically CME versus the ‘dinner meeting.’”
— Paula Kaptur, Manager, Medical Information, MedImmune
“This conference was very informative and addressed a lot of concerns that I feel need to be addressed or monitored.”
— Vermettya Hodge, Regulatory Associate II, MedImmune
“The level of detail covered by this conference has excellent and practical application.”
— Jill Dailey, Senior Commercial Attorney, Endo Pharmaceuticals
“This conference focused on the procedures to ensure that all is being done to stay in compliance.”
— Craig Conoscenti, Associate Director, Boehringer Ingelheim
“Big time value for pharmaceutical and medical device professionals managing brands through this ever changing and challenging regulatory climate.”
— Scott Sims, Director of Marketing, Mallinckrodt
“Speakers are excellent and information provided is well organized and presented.”
— Eugenio Angueira, Regional Scientific Director, Novo Nordisk
“A collection of top experts who imported timely information and useful guidance.”
— Gary Smith, VP & General Counsel, Enzon Pharmaceuticals
